News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Héctor Vaquera: Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma
Héctor Vaquera/X
May 24, 2025, 07:28

Héctor Vaquera: Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma

Héctor Vaquera, Research trainee at Hematology Department of UANL, shared a post on X:

“New publication
Here we synthethized available evidence on the use of low-doses of nivolumab for r/r HL, an alternative not-so-rarely used in LMICs.”

Title: Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review

Authors: Héctor A. Vaquera-Alfaro, José Emiliano Montelongo-Cepeda, Antonio Vega-Mateos, Anahí Morales-Pedraza, Haydeé Verduzco-Aguirre, David Gómez Almaguer, Luis Villela, Perla R. Colunga-Pedraza

You can read the Full Article on JCO Global Oncology.

Héctor Vaquera: Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma

More posts featuring Héctor Vaquera.

Anahí Morales-Pedraza Anti-PD1 Immune Checkpoint Inhibitors Antonio Vega-Mateos cancer Cancer research David Gomez-Almaguer Haydee Verduzco-Aguirre Héctor A. Vaquera-Alfaro Hodgkin lymphoma Immune Checkpoint Inhibitors José Emiliano Montelongo-Cepeda Luis Villela OncoDaily Oncology Perla R. Colunga-Pedraza
Special Coverage
Science
May 24, 2025, 07:28
Héctor Vaquera: Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma
Insight
May 24, 2025, 07:06
Heidi Ko Will Present a Poster on Immune Expression Profiles of Pancreatic Adenocarcinoma at ASCO 2025
Blog
May 24, 2025, 07:01
Damian Green Shares His Experience as Chief of the Division of Transplantation and Cellular Therapy at Sylvester Cancer Center
Blog
May 24, 2025, 06:43
Danny Burke: Ecancer Will Publish Educational Oncology Resources at the 2025 ASCO Annual Meeting
Blog
May 24, 2025, 06:40
Andrea Anampa-Guzmán Will Amplify Trainee Research on Drug Development, Survivorship Oncology and Global Oncology at ASCO 2025
Blog
May 24, 2025, 06:30
Chandler Park: AVENUES is the New Gold Standard for a Global Medical Education Meeting
Blog
May 24, 2025, 06:17
Mohamed Emam Sobeih: Thrilled to Participate CleaoAlfa Oncology Centre of Excellence Faculty Dinner 2025
Oncolibrary
May 24, 2025, 06:16
KEYNOTE-991 Trial Results: Pembrolizumab Plus Enzalutamide and ADT in mHSPC
Blog
May 24, 2025, 05:52
Robin Zon Shared New Podcast Episode with ASCO 2025 Meeting Scientific Program Chair Erika Hamilton
Blog
May 24, 2025, 05:41
Miriam Mutebi: Why Should You Attend AORTIC Networking Reception during ASCO 2025 Conference?
Insight
May 24, 2025, 05:26
Zainab Shinkafi-Bagudu: World Cervical Cancer Elimination Day Approved by WHO at the 78th WHA
Dialogues
May 24, 2025, 03:47
Dr. Lucia Viola on IASLC Nomination, Expanding Screening Access, and AI in Lung Cancer Care